#United States #Tampa #Concept Medical #Sirolimus #PAD Treatment

Concept Medical Announces Positive SIRONA Trial Results

Concept Medical, based in Tampa, Florida, has made significant strides in treating peripheral artery disease (PAD) through its innovative drug delivery technology. Recently, the company reported encouraging results from the SIRONA trial, a clinical study comparing its sirolimus-coated balloons (SCB) against commercially available paclitaxel-coated balloons.

SIRONA Trial Overview

The SIRONA trial, formally known as the "Head-to-Head Comparison of Sirolimus versus Paclitaxel Drug-Eluting Balloon Angioplasty in the Femoropopliteal Artery,” included 482 patients across 25 sites in Germany and Austria. This multi-center, randomized controlled trial aimed to determine the effectiveness and safety of sirolimus-based therapy for patients suffering from PAD.

The results revealed a primary patency rate of 73.8% for the MagicTouch PTA sirolimus-coated balloon, which is very close to the 75% rate recorded for paclitaxel-coated balloons. The slight difference of only 1.2% satisfies the trial’s non-inferiority efficacy endpoint. Both treatment options showed no significant difference in clinically-driven target lesion revascularization rates after 12 months, at 92.9% for the MagicTouch and 95.4% for the paclitaxel group.

Efficacy and Safety Considerations

Historically, paclitaxel has been the go-to therapy for PAD, particularly for the femoropopliteal region. However, recent safety concerns have sparked interest in exploring alternatives like sirolimus. With the SIRONA trial presenting evidence that sirolimus is just as effective as paclitaxel, physicians may be looking at a wider range of options for their PAD patients.

The results also indicated functional improvements with both therapies, with a minimal difference observed between the two groups. Notably, 89% of patients improved by at least one Rutherford stage, highlighting the effectiveness of both treatments.

Expert Endorsements

Prof. Ulf Teichgräber, the principal investigator, emphasized the significance of these findings: “With the SIRONA RCT showing sirolimus to be as effective as paclitaxel, physicians may soon have more personalized approaches to address the diverse needs of PAD patients.” Prof. Dierk Scheinert echoed this sentiment, stating that the results represent the first level one evidence supporting the clinical efficacy of the MagicTouch sirolimus-coated DCB for a broad spectrum of femoropopliteal blockages.

The Commitment to Innovation

Dr. Manish Doshi, the founder and managing director of Concept Medical, reiterated the company's commitment to innovation in vascular therapies. “The results of the SIRONA trial advance our mission to offer patient-centric, evidence-based solutions that improve the care for those affected by PAD.”

Concept Medical remains dedicated to developing next-generation vascular therapies aimed at improving patient outcomes, attributing its success to rigorous clinical research like the SIRONA trial. With over a million patients benefiting from its flagship product, the MagicTouch sirolimus-coated balloon, the company continues to reshape the landscape of coronary and peripheral interventions.

For further details about the SIRONA trial and Concept Medical's innovative solutions, please visit Concept Medical's website.